Data from post-mortem studies suggest that schizophrenia is associated with abnormal expression of GABAA receptor (GABAAR) a subunits including a5GABAA. Positron emission tomography (PET) measures of GABAAR binding in schizophrenic patients, however, have not revealed consistent alterations in vivo. Animal studies using the GABAAR agonist [ 3 H]muscimol have provided evidence that antipsychotic drugs used in schizophrenia can influence GABAAR binding, in a region-specific manner, complicating the interpretation of the PET GABA signal in medicated patients. No binding data, however, are available for more subunit-selective ligands. To address this, we combined a rodent model of clinically relevant antipsychotic drug exposure with quantitative receptor autoradiography. Haloperidol (0.5 and 2 mg/kg/day) or vehicle were continuously administered to adult male Sprague-Dawley rats via osmotic pumps to maintain a clinically relevant, steady-state levels of drug exposure for 28 days. Quantitative receptor autoradiography was then performed post-mortem using the GABAA selective radioligand [ 3 H]Ro15-4513 and the non-subunit selective radioligand [ 3 H]flumazenil. Chronic haloperidol exposure increased [ 3 H]Ro15-4513 binding in the CA1 sub-field of the dorsal hippocampus (p<0.01; q<0.01). [ 3 H]flumazenil binding was also increased in most of the explored regions (p<0.05), independently of the dose of haloperidol used. This is the first study to demonstrate a region/dose-specific effect of haloperidol on [ 3 H]Ro15-4513 binding.
Introduction
γ-Amino-butyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS). The GABAA receptor (GABAAR) is a pentameric GABA-gated chloride ion channel composed of several classes of subunits (α1-6, β1-3, γ1-3, δ, θ, ρ, and ɛ) [1] . Of these, the diversity of the a-subunit is thought to be responsible for shaping the functional properties and ligand selectivity of the GABAA benzodiazepine binding site (GABAA-BZR) [2] [3] [4] [5] . Benzodiazepines act at the α/γ interface for the α subunits 1, 3, 5 [6] . In the CNS, GABAA-BZR mediate pyramidal cell activity via tonic and phasic inhibition [7] [8] [9] .
Deficits in GABA neurotransmission, resulting in disruptions to normal patterns of neural oscillatory activity are implicated in the pathophysiology of schizophrenia [10] [11] [12] [13] . In support of this, quantitative receptor autoradiography studies using [ 3 H]muscimol, an orthosteric agonist at the GABA binding site on GABAA-BZR, provide consistent evidence for increased binding density in frontal and temporal cortices and the caudate nucleus in post-mortem brain tissue from patients with schizophrenia [14] [15] [16] [17] [18] [19] .
In contrast, post-mortem studies focusing specifically on mRNA expression of GABAA a-subunits report decreased expression of a1 [20, 21] , increased expression of a2 [21, 22] , but inconsistent results for the a5-subunit [21, 23, 24] . A systematic review of positron emission tomography (PET) studies in schizophrenia patients using selective radiotracers for the BZ-site of the GABAA-BZR however found no consistent evidence for altered GABAA-BZR availability in schizophrenia [25] .
These post-mortem data come from patients with a long duration of illness and exposure to antipsychotic medication. Similarly in most of the PET studies, the patients were also receiving antipsychotic medication [25] , and it has been shown that different antipsychotics can directly alter the binding of ligands to GABAA-BZR, presumably by altering the expression and availability of the receptors [26, 27] . Hence, distinguishing effect(s) of illness from antipsychotic exposure is challenging and medication may represent a significant source of heterogeneity in these data.
In support of this view, pre-clinical studies in naïve adult rats show that chronic exposure to antipsychotic haloperidol directly influences binding of both [ 3 H]muscimol (indexing GABAAR binding) and [ 3 H]flunitrazepam (indexing BZ-site binding) in a duration of exposure and region-dependent manner [28] [29] [30] [31] [32] [33] [34] [35] . These studies however have not been able to fully unravel this complex issue completely. While exposure of adolescent rats to antipsychotic drugs has recently been reported to increase [ 3 H]muscimol binding in the striatum and nucleus accumbens [36] a 12-day exposure to haloperidol is reported to decrease [ 3 H]flumazenil binding in several regions of the naïve rat brain [34] .
Collectively, these data strongly suggest that exposure to antipsychotic medication influences GABAA-BZR availability in vivo, but the direction of this effect remains ambiguous. Notably, these studies investigating effects of D2 dopaminergic receptor (D2R)-based antipsychotics on GABAA-BZR involved routes of administration that result in inappropriate pharmacokinetics that does not match a clinically comparable exposure [23] .
The binding sites to the GABAA-BZR allosteric ligand, [ 3 H]flumazenil, in the rodent and human brain have been shown to comprise both the "zolpidem-sensitive" and "zolpideminsensitive sites", with the latter suggested to correspond to GABAARs that contain the α5 subunit [38] . In a recent study, 12 days of systemic haloperidol exposure resulted in a significant reduction in zolpidem-sensitive binding sites (α1,2,3GABAAR [39] ), with no effect on the insensitive-binding sites, suggesting a lack of effect on α5GABAARs [34] . No studies however, have examined the potential impact of antipsychotic drug exposure using radioligands with greater selectivity for GABAA-BZR containing a1/a5 subunits, such as Ro15-4513 [40, 41] . This is relevant, since convergent lines of evidence from animal models strongly suggest that a5GABAAR have potential as a target for novel, non-dopaminergic antipsychotic compounds, by balancing hippocampal excitation via tonic inhibition of pyramidal neurons [42] [43] [44] [45] [46] [47] [48] [49] . Notably, the efficacy of the compound SH-053-2'F-R-CH3, an a5GABAAR positive allosteric modulator (PAM), in the methylazoxymethanol acetate (MAM) neurodevelopmental disruption model of schizophrenia is compromised following prior exposure to the D2R antagonist haloperidol [41] .
In the present study we therefore aimed to determine the impact of chronic exposure to haloperidol on GABAAR binding using post-mortem quantitative receptor autoradiography with [ 3 H]Ro15-4513 to assess a1/a5GABAAR and [ 3 H]flumazenil to assess BZ-sensitive a1-3;5GABAAR using a validated rat model of clinically comparable drug exposure [37, 50] . Based on the results of McLeod and colleagues (2008) who observed decreases in zolpidem-sensitive binding sites and no change in zolpideminsensitive sites after haloperidol exposure, we hypothesized that chronic haloperidol exposure would decrease [ 3 H]flumazenil binding, with no effect on [ 3 H]Ro15-4513 binding.
Methods

Animals and treatment protocol
Male Sprague-Dawley rats (N=36, Charles River, UK; ~ 10 weeks of age) were administered haloperidol (0.5 or 2 mg/kg/day; haloperidol; n=12/group: Sigma-Aldrich, Gillingham, Dorset, UK) or vehicle (β-hydroxypropylcyclodextrin, 20% w/v, acidified to pH 6 using ascorbic acid; n=12/group) using osmotic minipumps for 28 days [31] .
Dyskinetic behavior, i.e., vacuous chewing movements, was assessed once at 26 days after the start of haloperidol exposure. This involved a simple measurement of purposeless chewing jaw movements in a 2-minute period, outside the home cage as described previously [50] . All experimental procedures were performed in accordance with the relevant guidelines and regulations, specifically, the Home Office (Scientific Procedures) Act 1986, United Kingdom and European Union (EU) directive 2010/63/EU and the approval of the local Animal Welfare and Ethical Review Body (AWERB) panels at King's College London (for full details, see supplementary material).
Quantitative receptor autoradiography with [ 3 H]Ro15-4513 and [ 3 H]flumazenil
On completion of treatment, rats were terminally anesthetized and perfused. A plasma sample was collected for estimation of drug levels. Coronal 20 µm-thick sections were cut using a cryostat (Leica CM1950), mounted onto glass slides (Superfrost TM ) and stored at -80ºC until used for autoradiography (for further details, see supplementary material).
[ 3 H]Ro15-4513 (Perkin Elmer, NET925250UC) was used to quantify a1/5GABAAR density. While this ligand has a high specificity (60-70%) [51] to α5GABAAR, a smaller proportion of the binding has affinity to α1GABAAR [52] . Non-specific binding was determined by bretazenil (Sigma, B6434-25MG) due to its affinity to bind to a variety of GABAAR subtypes (α1-3;5) [53] . Sections were pre-incubated at room temperature in respectively, and exposed for 4 weeks before development.
Quantification of receptor binding
Films were developed and images were manually captured using a Nikon SLR camera and preprocessed (see supplementary material). Optical density (OD) measurements were obtained using MCID software (Imaging Research Inc., 2003) from a priori defined regions of interest (ROIs; Fig. 1 ). These were chosen based on the known distribution of a1/a5GABAAR in the rat brain, data from prior studies reporting an effect of haloperidol on [ 3 H]muscimol or [ 3 H]flunitrazepam binding [31] [32] [33] [34] , and a defined role in the pathophysiology of schizophrenia [31, 48, [54] [55] [56] [57] [58] . Specific binding in nCi/mg was quantified using standard curves constructed from OD measurements of standards for each film, using the robust linear regression interpolation method in GraphPad (version 8.00, GraphPad Software, La Jolla California USA www.graphpad.com). (4) (5) (6) layers was due to differential density of receptors across layers, specifically with α5 being more predominantly present in layer V and VI [59] . D) Caudate-Putamen (CPu), Nucleus Accumbens (NAc).
Statistical Analyses
All statistical analyses were performed in Prism software (v8.0.0 for Macintosh, GraphPad Software, La Jolla California USA, www.graphpad.com). The data were initially checked for significant outliers using Grubbs' test (a=0.05) with any significant outliers excluded from the final analysis. The data were then checked for Gaussian distribution using the Shapiro-Wilk normality test. Autoradiographic data were normally distributed (Shapiro-Wilk, p>0.05), but vacuous chewing movements scores were not (Shapiro-Wilk, p<0.01). Group-level differences in ligand binding were assessed using mixed-effects model, with ROI as within-subject factor and treatment (vehicle, haloperidol 0.5 or 2 mg/kg/day) as between-subject factor, using the specific binding the false discovery rate set at 5% (q<0.05) [60] . Relationships between vacuous chewing movements and ligand binding were modeled using non-parametric Spearman's Rho correlation (2-tailed).
Results
Haloperidol plasma levels and vacuous chewing movement behavior
Administration of haloperidol by osmotic pump achieved plasma levels (mean ± s.d.) of 2.96 ± 0.52 ng/mL and 12.2 ± 1.96 ng/mL, for dose haloperidol 0.5 and 2 mg/kg/day, respectively. Stereotypical vacuous chewing movement behaviors were significantly different across treatment group (Kruskal-Wallis statistic = 9.98; p<0.001; Fig. S1 ). Posthoc testing revealed a significant increase in vacuous chewing movements in those animals exposed to 2 mg/kg/day haloperidol after 26 days exposure, as compared to vehicle (p<0.01; q<0.05). There were no statistically significant differences between the haloperidol-exposed groups (p>0.05; q>0.05). Vacuous chewing movements were not related to the binding of either [ 3 H]Ro15-4513 (Table S1) (Table S2 ). Haloperidol plasma levels did not significantly correlate with binding of either of the ligands used (Table S3 ).
Dose-specific changes in [ 3 H]Ro15-4513 binding after haloperidol exposure measured with quantitative autoradiography
Mixed-effects model ANOVA revealed a statistically significant main effect of ROI (F(4,96)=106.2; p<0.0001) and a significant treatment*ROI interaction (F(24, 294)=1.71; p=0.02), but no statistically significant main effect of treatment (F(2, 28)=1.27; p=0.30).
Post-hoc testing on the ROI*treatment interaction revealed a statistically significant increase in [ 3 H]Ro15-4513 specific binding in the dCA1 of rats exposed to 0.5 mg/kg/day haloperidol, as compared to rats exposed to vehicle (p<0.01; q<0.01; Cohen's d=1. 3) or (4-6); Caudate-Putamen (CPu), Nucleus Accumbens (Nac); dorsal hippocampal layers CA1 (dCA1), CA2 (dCA2), CA3 (dCA3), dentate gyrus (DG); ventral hippocampal layers CA1 (vCA1), CA3 (vCA3); amygdala (Amy). *Vehicle vs. Haloperidol 0.5 mg/kg/day (q<0.01), # Haloperidol 0.5 mg/kg/day vs. Haloperidol 2 mg/kg/day (q<0.01), ## (q<0.001) 
General increase in [ 3 H]flumazenil binding after haloperidol exposure measured with quantitative autoradiography
Mixed-effects model ANOVA revealed a significant main effect of ROI (F=(4, 114)=124.2; p<0.0001) (Table S4, Figure S2 ) and treatment (F(2, 28)=3.86; p=0.03), but no ROI*treatment interaction (F (24, 304)=1.22; p=0.23). Across ROIs, the effect of haloperidol exposure was generally to increase [ 3 H]flumazenil-specific binding (see Table 2 and Figure 3 ). (4-6); Caudate-Putamen (Cpu), Nucleus Accumbens (Nac); dorsal hippocampal layers CA1 (dCA1), CA2 (dCA2),CA3 (dCA3), dentate gyrus (DG); ventral hippocampal layers CA1 (vCA1), CA3 (vCA3); amygdala (Amy). 
Discussion
To our knowledge, this is the first study to investigate the effects of chronic exposure to haloperidol using clinically comparable dosing on GABAAR binding in a receptor subtype-specific manner using quantitative autoradiography. The main findings are that chronic haloperidol exposure results in a dose-specific increase in [ 3 H]Ro15-4513 binding in the dCA1 of the hippocampus. Precisely, [ 3 H]Ro15-4513 binding is increased in rats exposed to haloperidol 0.5 mg/kg/day compared to rats exposed to vehicle with no effect of 2 mg/kg/day haloperidol. In contrast, chronic exposure to haloperidol generally increased [ 3 H]flumazenil binding in most ROIs irrespective of the dose administered. We found no relationship between these changes in ligand binding and vacuous chewing movements, a proxy measure for haloperidol-induced tardive dyskinesia, or drug plasma levels. These data suggest that chronic exposure to haloperidol has distinct, dose-and region-specific effects on the availability of GABAAR with specific sub-unit compositions. The present findings confirm that the dose and duration of exposure to haloperidol (and perhaps other antipsychotics) should be considered when measuring and interpreting GABAAR binding availability from schizophrenia patients.
Previous autoradiography studies have reported mixed findings regarding the effects of haloperidol exposure on GABAA-BZR binding sites. McLeod and Colleagues (2008) reported an overall decrease in [ 3 H]flumazenil binding across cortical and subcortical regions after a 12-day exposure to 1 mg/kg of haloperidol administered once daily via an intraperitoneal injection [34] . In contrast, using a more clinically relevant mode of administration and longer duration of exposure (28 vs. 12 days), our data suggest chronic haloperidol exposure results in a generalized increase in [ 3 H]flumazenil binding across several brain ROIs. The present findings are in concordance with previous research suggesting that chronic haloperidol exposure is associated with increased GABAA-BZR density in cortical areas using [ 3 H]flunitrazepam [32, 33] . The discrepancies between our findings and those in McLeod and colleagues (2008) could simply reflect methodological differences, due to the differing modes of drug administration [34] . Notably, intraperitoneal administration of haloperidol does not result in clinic-like steady-state plasma levels or pharmacokinetics [37] . Alternatively, there could be bi-phasic, timedependent effects of haloperidol exposure on GABAAR availability. McLeod and colleagues (2008) also reported no effect of 12-day haloperidol exposure on zolpideminsensitive [ 3 H]flumazenil binding, which is suggested to reflect a5GABAA binding sites [34, 38] . Hence, it may be speculated that [ 3 H]Ro15-4513 binding might be affected differently following shorter or longer exposure to haloperidol which should be explored by studying clinically-relevant dosages of antipsychotic medication at different time points.
The use of quantitative autoradiography in the present study provides proof-of-concept evidence that exposure to haloperidol affects GABAA-BZR as well as α5GABAAR specifically. This technique in pre-clinical research is highly advantageous as it provides better spatial resolution than PET studies and sets a translational framework for conducting clinical research with homologue ligands, which other techniques such as histology do not allow. Collectively, our findings and those of others suggest that haloperidol, a D2R antagonist, likely impacts on GABA neurotransmission within the hippocampal-midbrain loop circuitry, which is critically involved in emotion salience and memory and is dysregulated in schizophrenia [61] . Precisely how these drug-induced changes in GABAAR binding relate to central GABA neurotransmission however remains unclear. Quantitative autoradiography reflects changes in binding of the ligands to available receptor sites, which may relate to either upregulation or downregulation of neurotransmitter release. For example, an increase in receptor binding could indicate a compensatory effect in the form of a reduction in neurotransmitter levels. An increase in GABA levels does nonetheless also enhance affinity of GABAAR for BZ-ligands such as flumazenil via a conformational change [62] [63] [64] . This is not the case, for BZR inverse agonists such as Ro15-4513, in which increased GABA levels appear to decrease the affinity of GABAAR for this ligand [65] . Hence, increases in [ 3 H]flumazenil binding could reflect either increased or decreased GABA levels, whilst decreases in [ 3 H]Ro15-4513 binding likely reflect increases in GABA levels and vice versa. Taken together, our observations of increased [ 3 H]Ro15-4513 binding in the dCA1 following exposure to 0.5 mg/kg/day haloperidol may be interpreted as evidence for increases in membrane a1/5-GABAAR in response to decreased GABA levels [60] . In the higher-dose haloperidol group, we observed vacuous chewing movements, which in rats, it is an analogue measure to tardive dyskinesia observed in humans and can be an indicator of almost complete D2R blocking occupancy [66] , that may be causing differential effects on a1/5GABAAR than the lower-exposure dosages.
The overall increased [ 3 H]flumazenil binding could be suggestive of increased GABA release. Notably, in vitro slice electrophysiology suggests that D2R mediate GABA release onto pyramidal neurons in the PFC, whereby GABA release is decreased following dopamine administration [67] . D2R antagonists, such as haloperidol, would be predicted to increase GABA levels in the rodent frontal cortex, which could lead to elevated [ 3 H]flumazenil binding. In support of this view, GABA-immunoreactivity is increased in the axosomatic terminals of neurons in layers II, III, V, and VI in the frontal cortex of rats exposed chronically to 0.5 mg/kg/day haloperidol over 4 months [68] . In contrast, a microdialysis study in rats reported a decrease of extracellular levels of GABA in the nucleus accumbens region following chronic haloperidol exposure [61] , suggesting a compensatory upregulation of GABAAR in our sample of rats.
Studies of bulk tissue GABA levels in the frontal cortex of schizophrenia patients using proton magnetic resonance spectroscopy ( 1 H-MRS), however, report either no effect [70, 71] or a normalisation of elevated GABA levels [54] following antipsychotic exposure. The precise nature of the relationship between GABAAR binding and GABA levels following antipsychotic exposure therefore remains to be confirmed in future studies using corroborative methods, including microdialysis, 1 H-MRS and immunohistochemistry to map the cellular localization of these receptor changes. Of particular interest would be further exploration of the subiculum and dCA1 areas of the hippocampus, based on the present findings and on their involvement in the pathophysiology of psychosis [56, 61, 72] .
Limitations of our study should be noted. First, while [ 3 H]Ro15-4513 binds predominantly to diazepam-sensitive GABAA sites, it also binds to a diazepaminsensitive site in the cortex and hippocampus with lower affinity [73] , which should be taken into consideration when comparing [ 3 H]Ro15-4513's binding patterns to those of the BZ-sensitive ligand [ 3 H]flumazenil. Second, much of the binding was present within the lower-range of the commercially available standards, which limited the ability to detect a specific signal from regions with lower-binding values (likely reflecting lower receptor density). Hence, we may have underestimated or missed effects of haloperidol in such regions. Third, we only examined the effects of haloperidol; therefore, it is unclear whether the findings reported would generalize to other antipsychotic drugs such as olanzapine, aripiprazole and clozapine. In our previous studies concerning effects of haloperidol and olanzapine on brain volume and cellular markers, we found no clear differences between these compounds [74, 75] . Whilst we have no reason to believe that olanzapine for example, would not induce similar effects to haloperidol, this should be explicitly tested in future studies. Future studies should also address sex as a biological variable, since we only used male animals. Finally, it should be taken into consideration that the present data were collected in naïve animals, which do not recapitulate any features relevant to the pathophysiology of schizophrenia. Hence, haloperidol may act differentially on the GABA system in an initially dysregulated, diseased system. Future studies should therefore investigate the effects of antipsychotics on GABAAR in animal models reflective of genetic, environmental or pharmacological risk factors for psychosis.
In summary, our findings indicate that chronic treatment with haloperidol induces dosespecific changes in α1/5GABAAR in the dCA1 and a generalized increase in BZ-GABAAR in healthy rodents. These findings suggest that the mechanisms of action of antipsychotics may also involve the modulation of GABAAR in the midbrainhippocampal loop, predominantly implicating α1-3;5GABAAR. These mechanisms may be led more specifically by α5 receptors, particularly in the dCA1 and in a dose-specific manner. The present results align with the notion that administration of antipsychotics can change the responsivity to novel GABA-targeting drugs [76] . Importantly, the ligands used in this study to explore α5GABAAR (Ro15-4513) as well as BZ-sensitive GABAAR (flumazenil) offer promising approaches for translational research as they can be used in cross-species studies including PET in humans [77] .
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